Ferrocenylalkyl azoles: bioactivity, synthesis, structure

The toxicity of ferrocenylethyl benzotriazole (1) and other ferrocene compounds including ferrocenylmethyl benzimidazoles (4,5,6,11), ferricenium salts (3,9,10) and ferrocenylmethyl adenine (7), was studied. All ferrocene complexes under investigation showed low or medium toxicities. On the basis of an earlier model of chemical carcinogenesis, the antitumor activity of ferrocenylalkyl azoles 1, 8 and ferricenium salts 9, 10 was studied in vivo in the so-called sub-capsular test on human tumors. This effectiveness was compared with that of cisplatin. A series of ferrocenylalkyl azoles were synthesized by interacting azoles either with α-hydroxyalkyl ferrocenes FcC(OH)R1R2 in organic solvent in the presence of aqueous HBF4 in quantitative yields or with trimethyl(aminomethyl)ferrocene iodide in an aqueous-basic medium in good yields. The X-ray determinations of molecular and crystal structures of α-(1-benzotriazolyl)ethylferrocene (1) and α-(1-naphthatriazolyl)ethylferrocene (12) were performed. Copyright © 2008 John Wiley & Sons, Ltd.

[1]  E. Neuse.  Macromolecular Ferrocene Compounds as Cancer Drug Models , 2005 .

[2]  H. Kraatz.  Ferrocene-Conjugates of Amino Acids, Peptides and Nucleic Acids , 2005 .

[3]  N. Metzler‐Nolte,et al.  Bioorganometallic chemistry of ferrocene. , 2004, Chemical reviews.

[4]  V. N. Babin,et al.  Synthesis, structure and redox potentials of biologically active ferrocenylalkyl azoles , 2004 .

[5]  Y. Kuzmenko,et al.  Synthesis and enantiomeric resolution of ferrocenyl(alkyl)azoles , 2003 .

[6]  T. Hianik,et al.  Ferrocene-containing nucleic acids. Synthesis and electrochemical properties , 2003 .

[7]  W. Henderson,et al.  Platinum(II) complexes containing ferrocene-derived phosphonate ligands; synthesis, structural characterisation and antitumour activity , 2001 .

[8]  D. Osella,et al.  On the mechanism of the antitumor activity of ferrocenium derivatives , 2000 .

[9]  V. N. Babin,et al.  SYNTHESIS AND STRUCTURE OF BIOLOGICALLY ACTIVE FERROCENYLALKYL POLYFLUORO BENZIMIDAZOLES , 1999 .

[10]  C. E. J. Rensburg,et al.  Antineoplastic activity of polyaspartamide : Ferrocene conjugates , 1998 .

[11]  E. Neuse.  Carrier-bound platinum and iron compounds with carcinostatic properties , 1998 .

[12]  V. N. Babin,et al.  Structures of ferrocenylalkyl derivatives of adenine , 1998 .

[13]  H. Tamura,et al.  DNA Cleaving Activity and Cytotoxic Activity of Ferricenium Cations , 1997 .

[14]  D. Dexter,et al.  Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism. , 1995, Biochemical pharmacology.

[15]  V. N. Babin,et al.  The synthesis and structure of ferrocenylalkyl onium derivatives of nitrogen-containing heterocyclic compounds , 1995 .

[16]  V. N. Babin,et al.  Antitumor effects of binuclear ferrocene derivatives , 1993 .

[17]  A. Houlton,et al.  Studies on the anti-tumour activity of some iron sandwich compounds , 1991 .

[18]  E. Neuse,et al.  Metallocene-containing platinum complexes as potential antitumor agents. 1. Dichloro(1,6-differrocenyl-2,5-diazahexane)platinum(II) and cis-dichlorobis(1-ferrocenylethylamine)platinum(II) , 1988 .

[19]  E. Neuse,et al.  [Stability of ferricinium cations and their cytostatic effect]. , 1988, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[20]  P. Koepf-Maier,et al.  Non-platinum group metal antitumor agents. History, current status, and perspectives , 1987 .

[21]  R. Benoit,et al.  Protonation of purines and related compounds in dimethylsulfoxide and water , 1985 .

[22]  V. N. Babin,et al.  α-Ferrocenylalkylation of the benzotriazole anion , 1985 .

[23]  H. Köpf,et al.  Ferroceniumsalze ‐ die ersten tumorhemmenden Eisenverbindungen , 1984 .

[24]  H. Köpf,et al.  Ferrocenium Salts—The First Antineoplastic Iron Compounds , 1984 .

[25]  Shi-chow Chen.  The syntheses and mass spectra of some N-substituted ferrocenylmethyl adenines , 1980 .

[26]  A. Nesmejanow,et al.  Unmittelbare Cyanierung der Ferriciniumsalze , 1960 .

[27]  H. Rosenberg,et al.  Derivatives of Ferrocene. II. Some Reduction Products of Benzoylferrocene and 1,1'-Dibenzoylferrocene1 , 1957 .

[28]  N. Weliky,et al.  Studies in the Ferrocene Series. I. Some Reactions of Compounds Related to Monobenzoylferrocene1 , 1957 .

[29]  C. Hauser,et al.  Aminomethylation of Ferrocene to Form N,N-Dimethylaminomethylferrocene and Its Conversion to the Corresponding Alcohol and Aldehyde1 , 1957 .

[30]  A. C. Haven,et al.  Derivatives of Dicyclopentadienyliron1 , 1955 .

[31]  H. Köpf,et al.  Ferricenium complexes: A new type of water-soluble antitumor agent , 2004, Journal of Cancer Research and Clinical Oncology.

[32]  L. Rashan,et al.  Heterobimetallic complexes of platinum(II) with diferrocenylphenylphosphine and their in vitro activity against P388 leukaemia , 1999 .

[33]  W. Wilson,et al.  Electrochemically active threading intercalator with high double stranded DNA selectivity , 1998 .

[34]  V. N. Babin,et al.  A novel ferrocenylalkylating reagent. Ferrocenylalkylation of imidazole and its derivatives , 1997 .

[35]  A. Katritzky,et al.  Benzotriazole-mediated arylalkylation and heteroarylalkylation , 1994 .

[36]  F. Kanzawa,et al.  Evaluation of the activity of some water‐soluble ferrocene and ferricenium compounds against carcinoma of the lung by the human tumor clonogenic assay , 1990 .

[37]  J. Balzarini,et al.  Assessment of the in vitro broad‐spectrum antiviral activity of some selected antitumor metallocene and metallocenium complexes , 1989 .

[38]  N. Drake.  Organic Syntheses: an Annual Publication of Satisfactory Methods for the Preparation of Organic Chemicals , 1928, Nature.